Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA0RI9)

Drug Name
LIDORESTAT Drug Info
Synonyms
Lidorestat; 245116-90-9; IDD-676; UNII-R3734K0M7L; IDD-000676-01; {3-[(4,5,7-TRIFLUORO-1,3-BENZOTHIAZOL-2-YL)METHYL]-1H-INDOL-1-YL}ACETIC ACID; CHEMBL363387; R3734K0M7L; 1H-Indole-1-aceticacid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 3-[(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL]INDOLE-N-ACETIC ACID; 3NA; Lidorestat [USAN:INN]; 2-[3-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)methyl]indol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]-; 1H-Indole-1-acetic acid, 3-((4,5,7-trifluor
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 2 [1]
Cross-matching ID
PubChem CID
157839
CAS Number
CAS 245116-90-9
TTD Drug ID
DMA0RI9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Aldose reductase (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [3]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [4]
Fidarestat DMZL1I8 Diabetic complication 5A2Y Phase 3 [5]
Ranirestat DMD5QRS Diabetic neuropathy 8C0Z Phase 3 [6]
CONTIGOSIDE B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [7]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [6]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [8]
QR-333 DMKVIWM Diabetic neuropathy 8C0Z Phase 2 [9]
ADMVA DM819CO Diabetic complication 5A2Y Phase 2 [6]
M-16209 DMZ7YX3 Diabetic complication 5A2Y Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7411).
2 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
3 Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
4 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
5 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
7 Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
8 ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
9 A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
10 Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.